Living with Multiple Sclerosis (MS) often involves navigating various treatment options designed to manage the condition and slow its progression. 

Briumi vs Gilenya: A Comprehensive Look at MS Treatment Options

Living with Multiple Sclerosis (MS) often involves navigating various treatment options designed to manage the condition and slow its progression. Among the array of disease-modifying therapies (DMTs), oral medications offer convenience for many patients. Briumi (diroximel fumarate) and Gilenya (fingolimod) are two such oral treatments prescribed for relapsing forms of MS. While both aim to reduce relapse rates and lesion activity, they operate through different mechanisms and carry distinct profiles regarding efficacy, side effects, and administration.

Understanding the nuances between Briumi and Gilenya is crucial for individuals with MS and their healthcare providers when making informed treatment decisions. This article will provide a detailed comparison of these two significant medications.

Understanding Briumi (Diroximel Fumarate)

Briumi, known generically as diroximel fumarate, is an oral medication approved for the treatment of relapsing forms of MS. It is a newer fumarate derivative, closely related to dimethyl fumarate (Tecfidera).

Mechanism of Action

Briumi is a prodrug that is rapidly converted to monomethyl fumarate (MMF) in the body. While the exact mechanism of action in MS is not fully understood, MMF is believed to exert its therapeutic effects by activating the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. This pathway plays a crucial role in the body's response to oxidative stress and inflammation, leading to both anti-inflammatory and cytoprotective effects that may help protect nerve cells and reduce inflammation in the central nervous system.

Dosing and Administration

Briumi is taken orally, typically as a capsule twice daily. Treatment usually begins with a lower dose that is gradually increased over several days or weeks to the full therapeutic dose. It is generally recommended to take Briumi with food to help reduce gastrointestinal side effects.

Common Side Effects

The most common side effects associated with Briumi include gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain. Flushing (redness, itching, burning sensation) is also frequently reported. These side effects are often mild to moderate and tend to decrease over time. Other potential side effects can include lymphopenia (reduced white blood cell count) and changes in liver function tests, requiring periodic monitoring.

Understanding Gilenya (Fingolimod)

Gilenya, with the generic name fingolimod, was one of the first oral disease-modifying therapies approved for relapsing forms of MS. It represents a different class of medication compared to Briumi.

Mechanism of Action

Gilenya is a sphingosine 1-phosphate (S1P) receptor modulator. Once absorbed, fingolimod is phosphorylated to fingolimod-phosphate, which then binds to S1P receptors on lymphocytes (a type of white blood cell). This binding prevents lymphocytes from exiting the lymph nodes and entering the central nervous system (CNS). By reducing the number of lymphocytes circulating in the blood and entering the CNS, Gilenya helps to decrease inflammation and damage to nerve cells, thereby reducing MS relapses and the formation of new lesions.

Dosing and Administration

Gilenya is taken orally, once daily, as a capsule. A notable aspect of Gilenya treatment is the requirement for specific monitoring, especially around the first dose. Due to the risk of bradycardia (slow heart rate) and atrioventricular block, patients typically undergo a first-dose observation period in a medical setting, where their heart rate and rhythm are monitored for several hours.

Common Side Effects

Side effects of Gilenya can include initial bradycardia and atrioventricular block after the first dose. Other potential side effects include an increased risk of infections (due to reduced lymphocyte counts), elevated liver enzymes, macular edema (swelling in the eye), hypertension (high blood pressure), and headache. Regular ophthalmologic exams and blood tests are required to monitor for some of these risks.

Briumi vs Gilenya: A Direct Comparison

While both Briumi and Gilenya are effective oral treatments for relapsing MS, their differences are significant and can influence treatment choices.

Mechanism of Action Differences

The fundamental difference lies in how they target the immune system. Briumi works by activating the Nrf2 pathway, offering a broader anti-inflammatory and neuroprotective effect. Gilenya, on the other hand, specifically modulates S1P receptors to sequester lymphocytes in the lymph nodes, directly preventing them from attacking the CNS.

Efficacy Considerations

Both medications have demonstrated significant efficacy in reducing annualized relapse rates and slowing disease progression compared to placebo in clinical trials. While direct head-to-head trials comparing Briumi and Gilenya are limited, both are considered highly effective in their respective classes. The choice between them often depends on other factors rather than a clear superiority in efficacy across all patients.

Side Effect Profile Comparison

• Briumi: Tends to be associated with gastrointestinal issues (nausea, diarrhea, abdominal pain) and flushing. While these can be bothersome, they often lessen over time and are generally manageable.


• Gilenya: Has a more diverse and potentially more serious side effect profile, especially at treatment initiation. The first-dose cardiac monitoring is a unique requirement. Long-term risks include increased susceptibility to infections, specific eye conditions (macular edema), and liver function abnormalities.

Patients' individual tolerability to these distinct side effect profiles often plays a significant role in treatment selection.

Administration and Monitoring

• Briumi: Administered twice daily with food. Routine blood tests are necessary to monitor lymphocyte counts and liver function, but no specialized first-dose observation is typically required beyond general medical assessment.


• Gilenya: Administered once daily without regard to food. However, it requires a mandatory first-dose observation period for cardiac monitoring. Ongoing monitoring includes regular eye exams, blood pressure checks, and laboratory tests for lymphocyte counts and liver function.

Making an Informed Treatment Decision

Choosing between Briumi and Gilenya, or any MS DMT, is a highly personalized decision that should be made in close consultation with a neurologist or an MS specialist. Factors to consider include:

• Disease Activity: The current severity and progression of MS.


• Individual Health Profile: Presence of other medical conditions (e.g., cardiac issues, liver problems, diabetes) that might influence the safety profile of either drug.


• Previous Treatments: Response to and tolerability of past MS therapies.


• Patient Preferences: Lifestyle factors, willingness to undergo specific monitoring, and comfort with potential side effects.


• Potential Drug Interactions: Any other medications the patient is currently taking.

Conclusion

Both Briumi and Gilenya represent valuable oral treatment options for individuals living with relapsing forms of Multiple Sclerosis. Briumi, a newer fumarate, offers an anti-inflammatory and neuroprotective approach with a generally manageable gastrointestinal and flushing side effect profile. Gilenya, an S1P receptor modulator, works by preventing lymphocytes from entering the brain and spinal cord but carries specific risks requiring careful initial and ongoing monitoring, particularly for cardiac and ocular health. Understanding these distinct characteristics is vital. The optimal choice depends on a thorough discussion with your healthcare provider, weighing the potential benefits against the risks in the context of your unique medical history and personal preferences.